Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 11,201 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Urogenital Diseases Clear all
Completed Phase 1Phase 2 Interventional

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01240629
View directory record Official record
Conditions
Prostate Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
laboratory biomarker analysis, questionnaire administration, doxorubicin-GnRH agonist conjugate AEZS-108
Other · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

NCT00393029
View directory record Official record
Conditions
Anti-p53 TCR-Gene
Interventions
anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Phase 3 Interventional Results available

Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT01853553
View directory record Official record
Conditions
ADPKD
Interventions
Spironolactone, Sugar pill
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 17, 2026, 7:12 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Patient Satisfaction of Virtual vs In-Person Workup and Treatment of Lower Urinary Tract Symptoms.

NCT05508165
View directory record Official record
Conditions
Urologic Diseases
Interventions
Stream Dx, DFree, TestCard
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 7:12 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Angiotensin II in Liver Transplantation

NCT04901169
View directory record Official record
Conditions
Liver Transplant; Complications, Vasoplegia
Interventions
Angiotensin II, Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Not applicable Interventional

Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

NCT00056654
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Leuprolide acetate
Drug
Lead sponsor
Abbott
Industry
Eligibility
Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
55
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Not applicable Interventional Results available

Lubricant Versus Lidocaine Gel for Pain Control During Urodynamics

NCT01612156
View directory record Official record
Conditions
Pelvic Floor Disorders
Interventions
2% lidocaine gel, Water based lubricant
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 17, 2026, 7:12 PM EDT
Active, not recruiting Phase 1 Interventional Results available

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922
View directory record Official record
Conditions
Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Genetic · Radiation
Lead sponsor
USWM CT, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Phase 1 Interventional

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

NCT03454451
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
Interventions
CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 17, 2026, 7:12 PM EDT
Recruiting No phase listed Observational

Ablative Therapy in the Management of Prostate Cancer

NCT03492424
View directory record Official record
Conditions
Prostate Cancer
Interventions
cryotherapy
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2039
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise Intervention Metabolic Syndrome Prostate Cancer Black Men

NCT02379559
View directory record Official record
Conditions
Physical Activity, Metabolic Syndrome, Prostate Cancer
Interventions
Exercise, Attention Control
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 40 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Phase 1 Interventional

A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors

NCT02145559
View directory record Official record
Conditions
Breast Neoplasms, Lung Neoplasms, Cancer of Liver, Lymphoma, Cancer of Kidney
Interventions
Metformin XR, Delayed Metformin, Sirolimus
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 17, 2026, 7:12 PM EDT
Terminated Phase 3 Interventional

Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence

NCT00895479
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Graft placement surgery plus Trinam therapy
Procedure
Lead sponsor
Ark Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Long Beach, California • Paducah, Kentucky • Baton Rouge, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 17, 2026, 7:12 PM EDT
Terminated Phase 3 Interventional Results available

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

NCT04588246
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 17, 2026, 7:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

NCT03380962
View directory record Official record
Conditions
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 17, 2026, 7:12 PM EDT
Active, not recruiting Phase 2 Interventional

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

NCT04258462
View directory record Official record
Conditions
Benign Kidney Neoplasm, Kidney Neoplasm, Renal Cell Cancer
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Hyperpolarized 13C,15N2-urea
Drug · Procedure
Lead sponsor
Zhen Wang, MD
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Not applicable Interventional

The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer

NCT00605488
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions
novel PET tracer FACBC
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Phase 3 Interventional Results available

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

NCT00134056
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
atrasentan hydrochloride, docetaxel, prednisone, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
554
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Phase 3 Interventional Results available

A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

NCT05425056
View directory record Official record
Conditions
Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD, Chronic Kidney Failure, Complication of Hemodialysis, Vascular Access Complication, Arteriovenous Fistula
Interventions
Sirolimus
Drug
Lead sponsor
Vascular Therapies, Inc.
Industry
Eligibility
65 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
San Diego, California • Torrance, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Phase 1Phase 2 Interventional

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

NCT00094380
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
CTLA4-IgG4m (RG2077), Cyclophosphamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 17, 2026, 7:12 PM EDT
Terminated Phase 3 Interventional Results available

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

NCT00089141
View directory record Official record
Conditions
Cancer
Interventions
mycophenolate mofetil, placebo
Drug
Lead sponsor
Martin, Paul
Other
Eligibility
4 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 17, 2026, 7:12 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

NCT00301405
View directory record Official record
Conditions
Chronic Prostatitis, Pelvic Pain
Interventions
Thalidomide
Drug
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 17, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

NCT04935294
View directory record Official record
Conditions
Healthy, Renal Dysfunction
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 17, 2026, 7:12 PM EDT
Withdrawn Phase 1 Interventional

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

NCT02182622
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Prednisone, LDE225
Drug
Lead sponsor
Martin Gutierrez
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 17, 2026, 7:12 PM EDT